<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-154031</identifier>
<setSpec>0003-3170</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">One approach to treating vascular ulcers: Review and role of epidermal growth factor</dc:title>
<dc:description xml:lang="en">Review of scientific evidence and therapeutic options of recombinant human bioidentical epidermal growth factor (rhEGF) for vascular ulcers. Efficacy, with excellent tolerability and safety has been demonstrated with rhEGF, and it has been considered as an adjuvant or emerging treatment in evidence based clinical practice guidelines. rhEGF is available by magistral prescription, ensuring stability, effectiveness and safety, allowing individualisation (addition of active principles or dose personalisation). Compounds with rhEGF can be considered for managing vascular ulcers (AU)</dc:description>
<dc:creator>Herrero Vila, E</dc:creator>
<dc:creator>Esquirol Caussa, J</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Revisión de evidencia y opciones terapéuticas del factor de crecimiento epidérmico recombinante humano bioidéntico (rhEGF) en úlceras vasculares. El rhEGF ha evidenciado eficacia, tolerabilidad y seguridad, considerándose tratamiento adyuvante o emergente en guías de práctica clínica basadas en la evidencia. Se dispone de rhEGF mediante formulación magistral, asegurando estabilidad, efectividad y seguridad, permitiendo la individualización (adición de principios activos, cambios de galénica). Los compuestos con rhEGF mediante formulación magistral pueden considerarse indicados en el tratamiento de úlceras vasculares (AU)</dc:description>
<dc:source>Angiologia;68(4): 322-330, jul.-ago. 2016. tab</dc:source>
<dc:identifier>ibc-154031</dc:identifier>
<dc:title xml:lang="es">Un enfoque para el tratamiento de las úlceras de origen vascular: revisión y papel del factor de crecimiento epidérmico</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d1709^s22011</dc:subject>
<dc:subject>^d12413^s22031</dc:subject>
<dc:subject>^d1709^s22074</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d8049^s22067</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d1709^s22048</dc:subject>
<dc:subject>^d4896^s22073</dc:subject>
<dc:subject>^d4896^s22044</dc:subject>
<dc:subject>^d4896^s22000</dc:subject>
<dc:subject>^d1480^s22074</dc:subject>
<dc:subject>^d4896^s22015</dc:subject>
<dc:subject>^d13208^s22073</dc:subject>
<dc:subject>^d908^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>201608</dc:date>
</metadata>
</record>
</ibecs-document>
